Oncology Pipeline

Research & Development

Our Pipeline

At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today's challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients.

Servier’s pipeline includes many oncology assets at varying stages of clinical development

Hematological Malignancies

Molecule Area	Primary Indication	Partner	Territory	Phase

ONCASPAR^® (pegaspargase)	ALL		World	Registered
PRIMARY INDICATION Acute Lymphoblastic Leukemia		PARTNER		PARTNER World
PRIMARY INDICATION Acute Lymphoblastic Leukemia PARTNER TERRITORY World
	Acute Lymphoblastic Leukemia		World
ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase. Additional Information
ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase. Additional Information

ASPARLAS^™ (calaspargase pegol-mknl)	ALL		World	Registered
PRIMARY INDICATION Acute Lymphoblastic Leukemia		PARTNER		PARTNER World
PRIMARY INDICATION Acute Lymphoblastic Leukemia PARTNER TERRITORY World
	Acute Lymphoblastic Leukemia		World
ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years. Additional Information
ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years. Additional Information

TIBSOVO® (ivosidenib tablets)	IDH1-AML		World except for China	Registered
PRIMARY INDICATION IDH1-mutant Acute Myeloid Leukemia		PARTNER Acquired by Servier from Agios Pharmaceuticals in 2021		PARTNER World except for China
PRIMARY INDICATION IDH1-mutant Acute Myeloid Leukemia PARTNER Acquired by Servier from Agios Pharmaceuticals in 2021 TERRITORY World except for China
	IDH1-mutant Acute Myeloid Leukemia	Acquired by Servier from Agios Pharmaceuticals in 2021	World except for China
TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. Additional Information
TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. Additional Information

Idhifa ® (enasidenib)	IDH2-mutant R/R AML	Bristol Myers Squibb	United States	Registered
PRIMARY INDICATION IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia		PARTNER Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals		PARTNER United States
PRIMARY INDICATION IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia PARTNER Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals TERRITORY United States
	IDH2-mutant Relapsed or Refractory Acute Myeloid Leukemia	Servier acquired U.S. co-promotion and milestone rights for IDHIFA in 2021 from Agios Pharmaceuticals	United States
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. Additional Information
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. Additional Information

PIXURVI^® (pixantrone)	NHL		World	Registered
PRIMARY INDICATION Non-Hodgkin’s Lymphoma		PARTNER		PARTNER World
PRIMARY INDICATION Non-Hodgkin’s Lymphoma PARTNER TERRITORY World
	Non-Hodgkin’s Lymphoma		World
PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.
PIXURVI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

Anti-TIM-3	Lymphoma	Symphogen...	World	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World

MCL1 Inhibitor	AML	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Acute Myeloid Leukemia*		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Acute Myeloid Leukemia* PARTNER Novartis TERRITORY World except for North America and Japan
	Acute Myeloid Leukemia*	Novartis	World except for North America and Japan
*In combination with BCL-2 Inhibitor
*In combination with BCL-2 Inhibitor

BCL-2 Inhibitor	R/R AML + NHL + MM	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Acute Myeloid Leukemia + Non-Hodgkin’s Lymphoma + Multiple Myeloma	Novartis	World except for North America and Japan

BCL- 2 Inhibitor	R/R AML	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Acute Myeloid Leukemia PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Acute Myeloid Leukemia	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R NHL	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Non-Hodgkin’s Lymphoma	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R MM	Novartis	World except for North America and Japan	Phase 1
PRIMARY INDICATION Relapsed/Refractory Multiple Myeloma		PARTNER Novartis		PARTNER World except for North America and Japan
PRIMARY INDICATION Relapsed/Refractory Multiple Myeloma PARTNER Novartis TERRITORY World except for North America and Japan
	Relapsed/Refractory Multiple Myeloma	Novartis	World except for North America and Japan

BCL-2 Inhibitor	R/R CLL	Novartis	Phase 1
PRIMARY INDICATION R/R Chronic Lymphocytic Leukemia		PARTNER Novartis	PARTNER
PRIMARY INDICATION R/R Chronic Lymphocytic Leukemia PARTNER Novartis TERRITORY
	R/R Chronic Lymphocytic Leukemia	Novartis

Anti-CD19	R/R ALL Pediatric	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Acute Lymphoblastic Leukemia Pediatric*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-CD19	R/R ALL Adult	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Acute Lymphoblastic Leukemia Adult* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Acute Lymphoblastic Leukemia Adult*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-CD19	R/R NHL	Allogene Therapeutics	World except for the United States	Phase 1
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma*		PARTNER Allogene Therapeutics		PARTNER World except for the United States
PRIMARY INDICATION Relapsed/Refractory Non-Hodgkin’s Lymphoma* PARTNER Allogene Therapeutics TERRITORY World except for the United States
	Relapsed/Refractory Non-Hodgkin’s Lymphoma*	Allogene Therapeutics	World except for the United States
*Based on Cellectis TALEN® genome editing platform
*Based on Cellectis TALEN® genome editing platform

Anti-PD-1	Lymphoma	Symphogen...	World except for the United States	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World except for the United States
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World except for the United States
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World except for the United States

Anti-LAG-3	Lymphoma	Symphogen...	World	Phase 1
PRIMARY INDICATION Lymphoma		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.		PARTNER World
PRIMARY INDICATION Lymphoma PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. TERRITORY World
	Lymphoma	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence.	World

Ivosidenib	IDH1-mutant R/R MDS		World except for China	Phase 1
PRIMARY INDICATION Relapsed or Refractory Myelodysplastic Syndrome		PARTNER		PARTNER World except for China
PRIMARY INDICATION Relapsed or Refractory Myelodysplastic Syndrome PARTNER TERRITORY World except for China
	Relapsed or Refractory Myelodysplastic Syndrome		World except for China

Ivosidenib	IDH1-mutant IC-Ineligible Frontline AML		Phase 3
PRIMARY INDICATION Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia		PARTNER	PARTNER
PRIMARY INDICATION Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia PARTNER TERRITORY
	Intensive Chemotherapy-Ineligible Acute Myeloid Leukemia
An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment.
An ongoing phase 3 study, the AGILE trial is evaluating Ivosidenib + Azacitidine in adults with newly diagnosed AML and the IDH1 mutation who are not candidates for intensive treatment.

Ivosidenib	IDH1-mutant IC-Eligible Frontline AML		World except for China	Phase 3
PRIMARY INDICATION Intensive Chemotherapy-Eligible Acute Myeloid Leukemia		PARTNER		PARTNER World except for China
PRIMARY INDICATION Intensive Chemotherapy-Eligible Acute Myeloid Leukemia PARTNER TERRITORY World except for China
	Intensive Chemotherapy-Eligible Acute Myeloid Leukemia		World except for China
HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation
HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

Solid Tumors

Molecule Area	Primary Indication	Partner	Territory	Phase

Lonsurf^® (trifluridine/tipiracil)	mCRC Third Line	Taiho Pharmaceutical Co.	World except for the United States	Registered
PRIMARY INDICATION Third line metastatic Colorectal Cancer		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for the United States
PRIMARY INDICATION Third line metastatic Colorectal Cancer PARTNER Taiho Pharmaceutical Co. TERRITORY World except for the United States
	Third line metastatic Colorectal Cancer	Taiho Pharmaceutical Co.	World except for the United States
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Additional Information
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Additional Information

Lonsurf^® (trifluridine/tipiracil)	mCRC Second Line	Taiho Pharmaceutical Co.	World except for North America and Asia	Phase 1
PRIMARY INDICATION Second line metastatic Colorectal Cancer*		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION Second line metastatic Colorectal Cancer* PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	Second line metastatic Colorectal Cancer*	Taiho Pharmaceutical Co.	World except for North America and Asia
*In combination with oxaliplatin and nivolumab or bevacizumab Additional Information
*In combination with oxaliplatin and nivolumab or bevacizumab Additional Information

Lonsurf^® (trifluridine/tipiracil)	mCRC First Line	Taiho Pharmaceutical Co.	World except for North America and Asia	Phase 3
PRIMARY INDICATION First line metastatic Colorectal Cancer*		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION First line metastatic Colorectal Cancer* PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	First line metastatic Colorectal Cancer*	Taiho Pharmaceutical Co.	World except for North America and Asia
*In combination with bevacizumab
*In combination with bevacizumab

Lonsurf^® (trifluridine/tipiracil)	mGC Third Line		World except for North America and Asia	Registered
PRIMARY INDICATION Third line metastatic Gastric Cancer		PARTNER Taiho Pharmaceutical Co.		PARTNER World except for North America and Asia
PRIMARY INDICATION Third line metastatic Gastric Cancer PARTNER Taiho Pharmaceutical Co. TERRITORY World except for North America and Asia
	Third line metastatic Gastric Cancer	Taiho Pharmaceutical Co.	World except for North America and Asia
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. Additional Information
LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. Additional Information

Onivyde^® (Pegylated liposomal irinotecan)	mPAC post-gemcitabine	Ipsen	World except for the United States and Taiwan	Registered
PRIMARY INDICATION Metastatic Pancreatic Adenocarcinoma*		PARTNER Ipsen		PARTNER World except for the United States and Taiwan
PRIMARY INDICATION Metastatic Pancreatic Adenocarcinoma* PARTNER Ipsen TERRITORY World except for the United States and Taiwan
	Metastatic Pancreatic Adenocarcinoma*	Ipsen	World except for the United States and Taiwan
ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. *In combination with 5-FU/leucovorin Additional Information
ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. *In combination with 5-FU/leucovorin Additional Information

Vorasidenib	IDH-mutant Low-Grade Glioma		World	Phase 3
PRIMARY INDICATION IDH-mutant Low-Grade Glioma		PARTNER		PARTNER World
PRIMARY INDICATION IDH-mutant Low-Grade Glioma PARTNER TERRITORY World
	IDH-mutant Low-Grade Glioma		World
The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation.
The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation.

Anti-PD-1	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors: Programmed Cell Death Protein 1*		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **		PARTNER World
PRIMARY INDICATION Solid Tumors: Programmed Cell Death Protein 1* PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. ** TERRITORY World
	Solid Tumors: Programmed Cell Death Protein 1*	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **	World
Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3 *License option not yet exercised
Monotherapy and in combination with Anti-LAG-3 or Anti-TIM-3 *License option not yet exercised

Anti-LAG-3	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors- Lymphocyte-Activation Gene 3		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *		PARTNER World
PRIMARY INDICATION Solid Tumors- Lymphocyte-Activation Gene 3 PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. * TERRITORY World
	Solid Tumors- Lymphocyte-Activation Gene 3	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *	World
*License option not yet exercised
*License option not yet exercised

Anti-TIM-3	Solid Tumors	Symphogen...	World	Phase 1
PRIMARY INDICATION Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3		PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *		PARTNER World
PRIMARY INDICATION Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3 PARTNER Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. * TERRITORY World
	Solid Tumors- T-cell Immunoglobulin and Mucin Domain Protein 3	Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. *	World
*License option not yet exercised
*License option not yet exercised

Ivosidenib	Previously treated IDH1-mutant CCA		World except for China	Phase 1
PRIMARY INDICATION Previously treated IDH1-mutant Cholangiocarcinoma		PARTNER		PARTNER World except for China
PRIMARY INDICATION Previously treated IDH1-mutant Cholangiocarcinoma PARTNER TERRITORY World except for China
	Previously treated IDH1-mutant Cholangiocarcinoma		World except for China
Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting.
Ivosidenib was investigated in the ClarIDHy study, a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic therapies in the advanced setting.

AG-270	MTAP-Deleted Pancreatic Cancer		World	Phase 1
PRIMARY INDICATION Methylthioadenosine phosphorylase -deleted pancreatic cancer		PARTNER		PARTNER World
PRIMARY INDICATION Methylthioadenosine phosphorylase -deleted pancreatic cancer PARTNER TERRITORY World
	Methylthioadenosine phosphorylase -deleted pancreatic cancer		World

AG-270	MTAP-Deleted NSCLC		Phase 1
PRIMARY INDICATION Methylthioadenosine phosphorylase -deleted non-small cell lung cancer		PARTNER	PARTNER
PRIMARY INDICATION Methylthioadenosine phosphorylase -deleted non-small cell lung cancer PARTNER TERRITORY
	Methylthioadenosine phosphorylase -deleted non-small cell lung cancer

Oncology Pipeline

Research & Development

Our Pipeline

Hematological Malignancies

ONCASPAR®

(pegaspargase)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

ASPARLAS™

(calaspargase pegol-mknl)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

TIBSOVO®

(ivosidenib tablets)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

Idhifa ®

(enasidenib)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

PIXURVI®

(pixantrone)

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

Anti-TIM-3

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

MCL1 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL- 2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

PRIMARY INDICATION

PARTNER

PARTNER

PRIMARY INDICATION

PARTNER

TERRITORY

BCL-2 Inhibitor

ONCASPAR^®

ASPARLAS^™

PIXURVI^®